BODY FLUID ASSAY DEVICE

Inventor: Paul Laverack, Buckinghamshire (GB)
Assignee: Inverness Medical Switzerland GmbH, Zug (CH)
Term: 14 Years
Appl. No.: 29/285,313
Filed: Mar. 26, 2007

Foreign Application Priority Data
Sep. 27, 2006 (GB) 3026067

LOC (9) Cl. 24-01
U.S. Cl. D24/225
Field of Classification Search D24/216-230, D24/169, 186; D10/81; 422/56, 57, 58, 422/61, 68.1, 69, 70, 101, 104

References Cited
U.S. PATENT DOCUMENTS
D341,663 S * 11/1993 Coulter D24/225

Primary Examiner—T. Chase Nelson
Assistant Examiner—Anhdao Doan
Attorney, Agent, or Firm—Lalive & Cockfield, LLP

The ornamental design for a body fluid assay device, as shown and described.

DESCRIPTION


The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

FIG. 1 is a top plan view of a first embodiment of a body fluid assay device showing the design. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue.

FIG. 2 is a side view of a first embodiment of a body fluid assay device. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue.

FIG. 3 is a bottom plan view of a first embodiment of a body fluid assay device. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue.

FIG. 4 is a first end view of a first embodiment of a body fluid assay device. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue.

FIG. 5 is a second end view of a first embodiment of a body fluid assay device. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue.

FIG. 6 is a top plan view of a second embodiment of a body fluid assay device showing the design. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue. The blue color of this embodiment is defined according to the PANTONE™ Reflex Blue C.

FIG. 7 is a side view of a second embodiment of a body fluid assay device. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue. The blue color of this embodiment is defined according to the PANTONE™ Reflex Blue C.

FIG. 8 is a bottom plan view of a second embodiment of a body fluid assay device. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue. The blue color of this embodiment is defined according to the PANTONE™ Reflex Blue C.

FIG. 9 is a first end view of a second embodiment of a body fluid assay device. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue. The blue color of this embodiment is defined according to the PANTONE™ Reflex Blue C.

FIG. 10 is a second end view of a second embodiment of a body fluid assay device. A characteristic feature of the design resides in the color of a portion of the body fluid assay device being blue. The blue color of this embodiment is defined according to the PANTONE™ Reflex Blue C.

The broken lines in drawings are included for the purpose of illustrating a portion of the body fluid assay device that forms no part of the claimed design.

1 Claim, 2 Drawing Sheets
(2 of 2 Drawing Sheet(s)Filed in Color)
<table>
<thead>
<tr>
<th>Patent Number</th>
<th>Date</th>
<th>Inventor(s)</th>
<th>class</th>
</tr>
</thead>
<tbody>
<tr>
<td>D383,549 S</td>
<td>9/1997</td>
<td>Arnett et al.</td>
<td>D24/223</td>
</tr>
<tr>
<td>D432,244 S</td>
<td>10/2000</td>
<td>Anderson et al.</td>
<td>D24/223</td>
</tr>
<tr>
<td>6,372,516 B1</td>
<td>4/2002</td>
<td>Sun</td>
<td>422/104</td>
</tr>
<tr>
<td>D491,274 S</td>
<td>6/2004</td>
<td>Dubniczki et al.</td>
<td>D24/223</td>
</tr>
<tr>
<td>D493,893 S</td>
<td>8/2004</td>
<td>Wang</td>
<td>D24/223</td>
</tr>
<tr>
<td>D497,999 S</td>
<td>11/2004</td>
<td>Long</td>
<td>D24/223</td>
</tr>
<tr>
<td>D499,812 S</td>
<td>12/2004</td>
<td>Wu</td>
<td>D24/223</td>
</tr>
<tr>
<td>D509,901 S</td>
<td>9/2005</td>
<td>Phelan et al.</td>
<td>D24/223</td>
</tr>
<tr>
<td>D531,735 S</td>
<td>11/2006</td>
<td>Lee et al.</td>
<td>D24/223</td>
</tr>
<tr>
<td>D536,798 S</td>
<td>2/2007</td>
<td>Lee et al.</td>
<td>D24/223</td>
</tr>
<tr>
<td>7,300,627 B1</td>
<td>11/2007</td>
<td>Sun</td>
<td>422/58</td>
</tr>
</tbody>
</table>

* cited by examiner